| Filed On | Filing |
|---|---|
| 09 Nov 2026 | SCHEDULE 13G |
| 06 Nov 2026 | 10-Q |
| 06 Nov 2026 |
8-K: Results of Operations and Financial Condition
KIMMTRAK® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date |
| 07 Oct 2026 | SCHEDULE 13G/A |
| 14 Sep 2026 |
8-K: Regulation FD Disclosure
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 06 Aug 2026 | SCHEDULE 13G/A |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
KIMMTRAK® (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-year |
| 28 May 2026 |
Form 4: Ratcliffe Peter John, Director
Granted 27,492 Share Option (Right to Buy) |
| 28 May 2026 |
Form 4: Peterson Kristine, Director
Granted 27,492 Share Option (Right to Buy) |
| 28 May 2026 |
Form 4: Pao William, Director
Granted 27,492 Share Option (Right to Buy) |
| 28 May 2026 |
Form 4: Kaul Siddharth, Director
Granted 27,492 Share Option (Right to Buy) |
| 28 May 2026 |
Form 4: Herbst Roy Steven, Director
Granted 27,492 Share Option (Right to Buy) |
| 28 May 2026 |
Form 4: Bell John Irving, Director
Granted 27,492 Share Option (Right to Buy) |
| 27 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 27, 2026, Immunocore Holdings plc (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “AGM”). The shareholders considered the ten resolutions set forth below, each of which were voted on and duly passed on a ... |
| 22 May 2026 | 144 |
| 21 May 2026 | 144 |
| 15 May 2026 | SCHEDULE 13G |
Loading...